The incidences of tTMB-H (≥ 10 mut/Mb), analyzed in tumor tissue using the FoundationOne® CDx assay, and bTMB-H (≥ 10 mut/Mb), analyzed in blood using the FoundationOne® Liquid CDx assay, have been reported by cancer type (Fig. 4) [26]. This evidence concerns the gene TMEM200B and cancer.